For Osteoporosis and Osteopenia, Clinical Data and Thought Leaders' Opinions Indicate that AMG-785/CDP-7851 and Odanacatib Have

 For Osteoporosis and Osteopenia, Clinical Data and Thought Leaders' Opinions
Indicate that AMG-785/CDP-7851 and Odanacatib Have Advantages Over Alendronate

Greater Reduction in the Risk of Vertebral Fracture is One of the Greatest
Unmet Needs in Osteoporosis and Osteopenia, According to a New Report from
Decision Resources

PR Newswire

BURLINGTON, Mass., April 4, 2013

BURLINGTON, Mass., April 4, 2013 /PRNewswire/ --Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that surveyed U.S. and European primary care
physicians (PCPs) agree that efficacy on hip fracture risk reduction is one of
the attributes that most influences their decisions regarding prescribing in
osteoporosis and osteopenia. Clinical data and the opinions of interviewed
thought leaders indicate that Amgen/UCB's AMG-785/CDP-7851 and Merck's
odanacatib have advantages over patient share leader alendronate (Merck's
Fosamax, Teijin's Bonalon, generics) on this attribute.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled Emerging Therapies AMG-785/CDP-781 and
Odanacatib Are Poised to Overtake Teriparatide's Status as the Clinical Gold
Standard  also finds that, based on clinical data and the opinions of
interviewed thought leaders, teriparatide (Eli Lilly's Forteo/Forsteo, Asahi
Kasei's Teribone) is Decision Resources' current proprietary clinical
gold-standard therapy for osteoporosis and osteopenia. Teriparatide has the
strongest clinical profile among key marketed products that treat osteoporosis
and osteopenia. However, AMG-785/CDP-7851 is expected to displace teriparatide
and will earn proprietary clinical gold-standard status for osteoporosis and
osteopenia in 2021, following its launch for the indication in 2017.
AMG-785/CDP-7851 has competitive advantages in safety and tolerability as well
as delivery over teriparatide and advantages in efficacy and safety over the
current standard of care, alendronate.

"It is important to note, however, that AMG-785/CDP-7851 is considered only
marginally better than odanacatib, which falls just short of being the future
clinical gold standard," said Decision Resources Analyst Pam Narang, Ph.D.
"Furthermore, although thought leaders expect AMG-785/CDP-7851 to offer
superiority over alendronate across all efficacy attributes, the drug's
anticipated safety and tolerability profile gives it the edge over current and
emerging osteoporosis and osteopenia agents."

According to insights from surveyed U.S. and European PCPs and managed care
organization (MCO) pharmacy directors, greater reduction in the risk of
vertebral fracture is one of the greatest unmet needs in osteoporosis and
osteopenia. Clinical data and the opinions of interviewed thought leaders
indicate that Radius Health's BA-058 and AMG-785/CDP-7851 have demonstrated
the potential to significantly fulfill this unmet need.

The report also finds that surveyed U.S. MCO pharmacy directors are
particularly receptive to new osteoporosis and osteopenia therapies that offer
50 percent better reduction in the risk of vertebral fractures over currently
available therapies. Decision Resources expects that BA-058 and
AMG-785/CDP-7851 will match the improvements on vertebral fracture risk
reduction that surveyed U.S. payers indicated would be required for widespread
inclusion on MCO formularies.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Website: http://www.decisionresources.com
Contact: Christopher Comfort, Decision Resources, 781-993-2597,
ccomfort@dresources.com